Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; Department of Vascular Surgery, University Medical Center, Utrecht, The Netherlands.
Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
J Vasc Surg. 2018 Jan;67(1):206-216.e2. doi: 10.1016/j.jvs.2017.05.132. Epub 2017 Aug 24.
The optimal initial revascularization strategy remains uncertain for patients with peripheral arterial disease. The purpose of this study was to evaluate current nationwide selection and perioperative outcomes of patients undergoing bypass or endovascular intervention for infrainguinal disease in those with no prior ipsilateral revascularization.
Patients undergoing nonemergent first-time infrainguinal revascularization were identified in the Targeted Vascular module of the National Surgical Quality Improvement Program (NSQIP) for 2011 to 2014 and stratified by symptom status (chronic limb-threatening ischemia [CLTI] or claudication). Patients treated with endovascular intervention were compared with those who underwent bypass. Multivariable logistic regression was used to evaluate current selection of patients and to establish independent associations between first-time procedures and postoperative outcomes.
Of 5998 first-time infrainguinal revascularizations performed, 3193 were bypass procedures (63% for CLTI) and 2805 were endovascular interventions (64% for CLTI). Current patient characteristics associated with an endovascular-first approach as opposed to bypass-first in CLTI patients were age ≥80 years, tissue loss, nonsmoking, functional dependence, diabetes, dialysis, and tibial lesions, whereas age ≥80 years, nonwhite race, nonsmoking, diabetes, and tibial lesions were associated with an endovascular approach for claudication. In comparing first-time endovascular intervention with bypass, there was no difference in 30-day mortality in CLTI patients (univariate: 2.1% vs 2.2%; adjusted: odds ratio [OR], 0.7; 95% confidence interval [CI], 0.4-1.1) or claudication patients (0.3% vs 0.6%). Among CLTI patients, endovascular-first intervention was associated with lower rates of major adverse cardiovascular event (3.6% vs 4.7%; OR, 0.6; 95% CI, 0.4-0.9), surgical site infection (0.9% vs 7.7%; OR, 0.1; 95% CI, 0.1-0.2), bleeding (8.5% vs 17%; OR, 0.4; 95% CI, 0.3-0.5), unplanned reoperation (13% vs 17%; OR, 0.7; 95% CI, 0.5-0.8), and unplanned readmission (17% vs 18%; OR, 0.8; 95% CI, 0.7-0.9). Patients with claudication undergoing endovascular-first intervention also had lower rates of major adverse cardiovascular event (0.8% vs 1.6%; OR, 0.4; 95% CI, 0.2-0.95), surgical site infection (0.7% vs 6.6%; OR, 0.1; 95% CI, 0.04-0.2), bleeding (2.3% vs 6.0%; OR, 0.3; 95% CI, 0.2-0.5), unplanned reoperation (4.3% vs 6.6%; OR, 0.6; 95% CI, 0.4-0.9), and unplanned readmission (5.9% vs 9.0%; OR, 0.6; 95% CI, 0.4-0.8). Conversely, endovascular-first intervention was associated with a higher rate of secondary revascularizations within 30 days for CLTI (4.3% vs 3.1%; OR, 1.6; 95% CI, 1.04-2.3) but not for claudication (2.6% vs 1.9%; OR, 1.7; 95% CI, 0.9-3.4).
An endovascular-first approach as a revascularization strategy for infrainguinal disease was associated with substantially lower early morbidity but not mortality, at the cost of higher rates of postoperative secondary revascularizations. As a national representation of first-time revascularizations, this study highlights the early endovascular perioperative benefit, although more robust long-term data are needed to adopt either one strategy or the other in select patients with peripheral arterial disease.
对于外周动脉疾病患者,最佳初始血运重建策略仍不确定。本研究旨在评估无同侧血运重建史的患者进行旁路或腔内干预治疗下肢动脉疾病时,目前选择的治疗策略和围手术期结果。
在 2011 年至 2014 年期间,通过国家手术质量改进计划(NSQIP)的靶向血管模块,确定了首次接受非紧急下肢血运重建的患者,并根据症状状况(慢性肢体威胁性缺血[CLTI]或跛行)进行分层。比较腔内介入治疗与旁路治疗的患者。多变量逻辑回归用于评估当前患者的选择,并确定首次手术与术后结果之间的独立关联。
在 5998 例首次下肢血运重建中,3193 例为旁路手术(63%为 CLTI),2805 例为腔内介入治疗(64%为 CLTI)。目前与 CLTI 患者首选腔内介入而非旁路手术相关的患者特征包括年龄≥80 岁、组织丢失、不吸烟、功能依赖、糖尿病、透析和胫骨病变,而年龄≥80 岁、非白人种族、不吸烟、糖尿病和胫骨病变与 CLTI 患者的腔内介入治疗相关。比较首次腔内介入与旁路治疗,CLTI 患者 30 天死亡率无差异(单变量:2.1% vs 2.2%;调整后优势比[OR],0.7;95%置信区间[CI],0.4-1.1)或跛行患者(0.3% vs 0.6%)。在 CLTI 患者中,腔内介入优先治疗与较低的主要不良心血管事件发生率相关(3.6% vs 4.7%;OR,0.6;95%CI,0.4-0.9)、手术部位感染(0.9% vs 7.7%;OR,0.1;95%CI,0.1-0.2)、出血(8.5% vs 17%;OR,0.4;95%CI,0.3-0.5)、计划外再次手术(13% vs 17%;OR,0.7;95%CI,0.5-0.8)和计划外再入院(17% vs 18%;OR,0.8;95%CI,0.7-0.9)。行腔内介入优先治疗的跛行患者也具有较低的主要不良心血管事件发生率(0.8% vs 1.6%;OR,0.4;95%CI,0.2-0.9)、手术部位感染(0.7% vs 6.6%;OR,0.1;95%CI,0.04-0.2)、出血(2.3% vs 6.0%;OR,0.3;95%CI,0.2-0.5)、计划外再次手术(4.3% vs 6.6%;OR,0.6;95%CI,0.4-0.9)和计划外再入院(5.9% vs 9.0%;OR,0.6;95%CI,0.4-0.8)。相反,腔内介入优先治疗与 CLTI 患者 30 天内二次血运重建的发生率较高相关(4.3% vs 3.1%;OR,1.6;95%CI,1.04-2.3),但与跛行患者无关(2.6% vs 1.9%;OR,1.7;95%CI,0.9-3.4)。
作为下肢动脉疾病的血运重建策略,腔内介入优先治疗与早期较低的发病率相关,但死亡率无差异,代价是术后二次血运重建的发生率较高。作为首次血运重建的全国代表性研究,本研究强调了腔内介入治疗的早期围手术期获益,尽管需要更有力的长期数据来在选择的外周动脉疾病患者中采用这两种策略中的一种。